{"schema_version":"1.0","type":"article","title":"憂鬱新藥三期成功，下場試驗驗證重現","url":"https://drugnews.com.tw/articles/2026-11-21-helus-hlp003-depression-phase3.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-21-helus-hlp003-depression-phase3.md","lang":"zh-Hant","date":"2026-11-21","publish_at":"2026-11-21T08:00:00+08:00","updated_at":"2026-11-21","category":"商業分析系列","topic":"臨床與 CMC","tags":["憂鬱症","精神醫學","臨床試驗","Helus"],"summary":"HLP003 三期結果支持繼續開發；下一步看 EMBRACE 能否重現療效，成功仍須完整效益風險與監管審查。","key_points":["APPROACH 支持繼續開發；HLP003 的產品差異化須以 EMBRACE 重現與可交付照護驗證。","APPROACH 的組間差支持新增療效；不同研究人群不能直接排名。","台灣可近性牽涉在地許可、支付安排與院所交付。"],"facts":[{"claim":"事件最早公開日","value":"2026-11-16","unit":"date","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"APPROACH研究階段","value":3,"unit":"phase","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第6週主要評估時點","value":6,"unit":"week","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第6週安慰劑校正MADRS差","value":-7.6,"unit":"point","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第12週關鍵次要評估時點","value":12,"unit":"week","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第12週安慰劑校正MADRS差","value":-7,"unit":"point","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第6週HLP003緩解率","value":50.9,"unit":"percent","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第6週安慰劑緩解率","value":18.2,"unit":"percent","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"緩解門檻MADRS","value":10,"unit":"point_upper_bound","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"同研究緩解率絕對差","value":32.7,"unit":"percentage_point","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"NNT未取整","value":3.058103975535168,"unit":"person","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"NNT向上取整","value":4,"unit":"person","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"治療相關嚴重不良事件","value":3,"unit":"event","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"EMBRACE公司預期讀出","value":"2027-Q4","unit":"forecast","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"SPRAVATO給藥後觀察下限","value":2,"unit":"hour","as_of":"2026-11-17","source":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf"}],"sections":["01｜先扣掉安慰劑，才看得見新增效果","02｜三家公司比的是證據成熟度","03｜緩解率很好看，下一關是重現與安全性","04｜台灣：從監測文件走到本地治療","參考資料"],"references":[{"title":"APPROACH positive topline results","source":"Helus Pharma","date":"2026-11-16","url":"https://ir.helus.com/node/11511/pdf"},{"title":"APPROACH trial record NCT06564818","source":"ClinicalTrials.gov","date":"","url":"https://clinicaltrials.gov/study/NCT06564818"},{"title":"EMBRACE trial record NCT06793397","source":"ClinicalTrials.gov","date":"","url":"https://clinicaltrials.gov/study/NCT06793397"},{"title":"EXTEND trial record NCT06605105","source":"ClinicalTrials.gov","date":"","url":"https://clinicaltrials.gov/study/NCT06605105"},{"title":"SPRAVATO prescribing information","source":"FDA","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf"},{"title":"SPRAVATO monotherapy approval announcement","source":"Johnson & Johnson","date":"2025-01-21","url":"https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression"},{"title":"COMP360 second Phase 3 follow-up","source":"Compass Pathways","date":"2026-07-07","url":"https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/default.aspx"},{"title":"Psychedelic Drugs: Considerations for Clinical Investigations","source":"FDA","date":"","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations"},{"title":"SPRAVATO 速開朗鼻噴劑仿單","source":"高雄市立凱旋醫院刊載","date":"","url":"https://ksph.kcg.gov.tw/7/dfiles_pdf/Spravato.pdf"},{"title":"用藥安全","source":"衛生福利部","date":"","url":"https://www.mohw.gov.tw/cp-88-216-1.html"},{"title":"全民健康保險藥物給付項目及支付標準","source":"全國法規資料庫","date":"","url":"https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0060035"}],"images":[{"alt":"圖1｜安慰劑校正效果","url":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3/figure-01.png"},{"alt":"圖2｜血清素作用的機制假說","url":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3/figure-02.png"},{"alt":"圖3｜由緩解率計算絕對效益","url":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3/figure-03.png"},{"alt":"圖4｜台灣的治療交付流程","url":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-21）。憂鬱新藥三期成功，下場試驗驗證重現。https://drugnews.com.tw/articles/2026-11-21-helus-hlp003-depression-phase3.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「APPROACH 支持繼續開發」有哪些關鍵變化？","a":"APPROACH 支持繼續開發；HLP003 的產品差異化須以 EMBRACE 重現與可交付照護驗證。"},{"q":"「APPROACH 的組間差支持新增療效」有哪些關鍵變化？","a":"APPROACH 的組間差支持新增療效；不同研究人群不能直接排名。"},{"q":"「台灣可近性牽涉在地許可、支付安排與院所交付」有哪些關鍵變化？","a":"台灣可近性牽涉在地許可、支付安排與院所交付。"}]}